PALI Valuation

Palisade Bio Inc

Add to Watchlist

Advanced Chart

0.726

+0.006(0.833%)1D

Overview
Forecast
Valuation
Earnings

PALI Relative Valuation

PALI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PALI is overvalued; if below, it's undervalued.

Historical Valuation

Palisade Bio Inc (PALI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.97. The fair price of Palisade Bio Inc (PALI) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：0.72

Fair

-0.47

Trailing

Forward

0.00

EV/EBITDA

Palisade Bio Inc. (PALI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.08

EV/EBIT

Palisade Bio Inc. (PALI) has a current EV/EBIT of -0.08. The 5-year average EV/EBIT is -0.03. The thresholds are as follows: Strongly Undervalued below -1.56, Undervalued between -1.56 and -0.79, Fairly Valued between 0.73 and -0.79, Overvalued between 0.73 and 1.50, and Strongly Overvalued above 1.50. The current Forward EV/EBIT of -0.08 falls within the Historic Trend Line -Fairly Valued range.

0.00

Palisade Bio Inc. (PALI) has a current PS of 0.00. The 5-year average PS is 9.20. The thresholds are as follows: Strongly Undervalued below -36.04, Undervalued between -36.04 and -13.42, Fairly Valued between 31.82 and -13.42, Overvalued between 31.82 and 54.44, and Strongly Overvalued above 54.44. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Palisade Bio Inc. (PALI) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.42. The thresholds are as follows: Strongly Undervalued below -1.88, Undervalued between -1.88 and -1.15, Fairly Valued between 0.32 and -1.15, Overvalued between 0.32 and 1.05, and Strongly Overvalued above 1.05. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Palisade Bio Inc. (PALI) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.35. The thresholds are as follows: Strongly Undervalued below -1.33, Undervalued between -1.33 and -0.84, Fairly Valued between 0.14 and -0.84, Overvalued between 0.14 and 0.63, and Strongly Overvalued above 0.63. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Palisade Bio Inc (PALI) has a current Price-to-Book (P/B) ratio of 1.42. Compared to its 3-year average P/B ratio of 0.50 , the current P/B ratio is approximately 184.96% higher. Relative to its 5-year average P/B ratio of -718.78, the current P/B ratio is about -100.20% higher. Palisade Bio Inc (PALI) has a Forward Free Cash Flow (FCF) yield of approximately -132.30%. Compared to its 3-year average FCF yield of -254.87%, the current FCF yield is approximately -48.09% lower. Relative to its 5-year average FCF yield of -200.27% , the current FCF yield is about -33.94% lower.

1.32

P/B

Median3y

0.50

Median5y

-718.78

-136.69

FCF Yield

Median3y

-254.87

Median5y

-200.27

Competitors Valuation Multiple

The average P/S ratio for PALI's competitors is 12.59, providing a benchmark for relative valuation. Palisade Bio Inc Corp (PALI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Sunshine Biopharma Inc

Cyclerion Therapeutics Inc

3.68

7.94M

Performance Decomposition

Market capitalization of PALI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PALI in the past 1 year is driven by Unknown.